Why are unproven stem cell treatments a concern for patients and regulators?

Created from Britannica articles using AI. AI can make mistakes, so verify using Britannica articles.

Diagram showing the locations of neural stem cells in brain regions such as the hippocampus and ventricles, and hematopoietic stem cells in the bone marrow and blood, with labeled illustrations of the brain, spinal cord, circulatory system, and skeleton. — stem cell Stem cells of neural and hematopoietic origin have tremendous potential in the development of therapies for certain diseases, such as diabetes and Parkinson disease. Neural stem cells occur in the spinal cord and in specific regions of the brain, and hematopoietic stem cells occur in the blood and bone marrow.

Unproven stem cell treatments are a significant concern for patients and regulators because they are marketed without the rigorous scientific validation required for safe and effective medical practice. While stem cells hold immense potential for regenerative medicine, the commercialization of experimental therapies that have not undergone established clinical trials poses serious risks to patient safety.1

Ethically, it is imperative to protect vulnerable individuals from exploitation and potential harm. Regulators are concerned that the aggressive marketing of these unproven treatments can mislead patients, potentially leading them to forgo conventional medical care or suffer adverse health consequences from unregulated procedures. Ensuring that medical interventions are evidence-based is a fundamental ethical principle, as it upholds the duty to "do no harm" and maintains the integrity of the healthcare system.1

The scientific community continues to emphasize that while research into induced pluripotent stem (iPS) cells and other therapies is promising, the transition from laboratory discovery to clinical application must be governed by strict oversight to ensure patient welfare and scientific accuracy.1